<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02388984</url>
  </required_header>
  <id_info>
    <org_study_id>TCM9001-04</org_study_id>
    <nct_id>NCT02388984</nct_id>
  </id_info>
  <brief_title>Phase III Study of Compound Danshen Dripping Pills to Treat Diabetic Retinopathy</brief_title>
  <official_title>A Randomized, Double Blind, Multi-Center Study of Compound Danshen Dripping Pills in Patients With Diabetic Retinopathy (Syndrome Of Qi-Stagnation and Blood Stasis)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Tasly Pharmaceuticals, Inc.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Tasly Pharmaceuticals, Inc.</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to evaluate the efficacy and safety of Compound Danshen Dripping&#xD;
      Pills in patients with diabetic retinopathy(Syndrome Of Qi-Stagnation and Blood Stasis).&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Compound danshen dripping pills is a kind of traditional Chinese medicine(TCM), consists of&#xD;
      Danshen (Radix Salviae Miltiorrhizae), Sanqi (Radix Notoginseng) and borneol. This study is&#xD;
      being conducted to evaluate the efficacy and safety of compound danshen dripping pills in&#xD;
      patients with diabetic retinopathy(Syndrome Of Qi-Stagnation and Blood Stasis), when compared&#xD;
      with placebo.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Active, not recruiting</last_known_status>
  <start_date>May 2013</start_date>
  <completion_date type="Anticipated">December 2017</completion_date>
  <primary_completion_date type="Anticipated">May 2017</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>The total effective rate of Fundus changes, the severity of diabetic retinopathy change from baseline at the end of week 24 compared to placebo</measure>
    <time_frame>24weeks</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Symptoms scores of TCM change from baseline at the end of week 24 compared to placebo</measure>
    <time_frame>24 weeks.</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Corrected visual acuity change from baseline at the end of week 24 compared to placebo</measure>
    <time_frame>24 weeks.</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>The severity of macular edema change from baseline at the end of week 24 compared to placebo</measure>
    <time_frame>24weeks</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">480</enrollment>
  <condition>Non-proliferative Diabetic Retinopathy</condition>
  <arm_group>
    <arm_group_label>Compound danshen dripping pills</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Compound danshen dripping pills,20pills,tid. Duration: 24 weeks.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Placebo,20pills,tid. Duration: 24 weeks.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Compound danshen dripping pills</intervention_name>
    <description>Dosage form:pill. Dosage:20pills. Frequency:three times per day. Duration:24 weeks.</description>
    <arm_group_label>Compound danshen dripping pills</arm_group_label>
    <other_name>Dantonic®</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Dosage form:pill. Dosage:20pills. Frequency:three times per day. Duration:24 weeks.</description>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Diagnosed with non-proliferative diabetic retinopathy(NPDR) and TCM syndrome&#xD;
             differentiation of qi-stagnation and blood stasis.&#xD;
&#xD;
          2. aged 30-70 years&#xD;
&#xD;
          3. voluntary signs the informed consent&#xD;
&#xD;
        One eye met the inclusion criteria can be used as research object, if both eyes met the&#xD;
        inclusion criteria, please record respectively, and select one eye for efficacy evaluation&#xD;
        with reference to the following principles:&#xD;
&#xD;
        When the two eyes of fundus conditions in different clinical stage, choose the more serious&#xD;
        one.&#xD;
&#xD;
        When the two eyes of fundus conditions in the same clinical stage, choose the eye easier&#xD;
        for clinical operation.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. HbAlc&gt;8%, sustained hyperglycemia.&#xD;
&#xD;
          2. The patients who have been received the therapy of Retina laser photocoagulation or&#xD;
             diagnosed with proliferative diabetic retinopathy (one or two eyes).&#xD;
&#xD;
          3. Diabetic retinopathy caused by type 1 diabetes mellitus.&#xD;
&#xD;
          4. Combined with glaucoma, uveitis, ocular neuropathy and severe cataract etc.&#xD;
&#xD;
          5. Combined with primarily severe diseases such as cardiovascular, hepatic，renal illness&#xD;
             , hemopoietic system disease, and psychosis. Serum transaminase is higher than the&#xD;
             limit of normal value of 1.5 times.&#xD;
&#xD;
          6. Diabetic nephropathy with renal failure (Azotemia or Uremia).&#xD;
&#xD;
          7. For women of child-bearing potential: pregnant or lactating or intending to become&#xD;
             pregnant. Having any allergic reaction to some drugs.&#xD;
&#xD;
          8. Participated in other clinical trial within 3 months.&#xD;
&#xD;
          9. Used drugs for the treatment of diabetic retinopathy within 1 week.&#xD;
&#xD;
         10. Blood pressure &gt; 160/100 (systolic above 160 or diastolic above 100).&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>30 Years</minimum_age>
    <maximum_age>70 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Min Zhao, PhD</last_name>
    <role>Study Director</role>
    <affiliation>Tasly Group, Co. Ltd.</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Guang'anmen Hospital of China Academy of Chinese Medical Sciences</name>
      <address>
        <city>Bei Jing</city>
        <state>Beijing</state>
        <zip>100053</zip>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Dongfang Hospital, Beijing University of Chinese Medicine</name>
      <address>
        <city>Bei Jing</city>
        <state>Beijing</state>
        <zip>100078</zip>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Southwest Hospital, Third Military Medical University</name>
      <address>
        <city>Chong Qing</city>
        <state>Chongqing</state>
        <zip>400038</zip>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>The First Affiliated Hospital of Guangzhou University of TCM</name>
      <address>
        <city>Guang Zhou</city>
        <state>Guangdong</state>
        <zip>510405</zip>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>The First Affiliated Hospital of Guangxi Medical University</name>
      <address>
        <city>Nan Ning</city>
        <state>Guangxi</state>
        <zip>530021</zip>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Henan Institute of Ophthalmology</name>
      <address>
        <city>Zheng Zhou</city>
        <state>Henan</state>
        <zip>450003</zip>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hubei Provincial Hospital of TCM</name>
      <address>
        <city>Wu Han</city>
        <state>Hubei</state>
        <zip>430022</zip>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Union Hospital, Tongji Medical College,Huazhong University of Science and Technology</name>
      <address>
        <city>Wu Han</city>
        <state>Hubei</state>
        <zip>430022</zip>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>The First Hospital of Hunan University of Chinese Medicine</name>
      <address>
        <city>Chang Sha</city>
        <state>Hunan</state>
        <zip>410000</zip>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Jiangsu Province Hospital of TCM</name>
      <address>
        <city>Nan Jing</city>
        <state>Jiangsu</state>
        <zip>210029</zip>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Jiangxi Provincial People's Hospital</name>
      <address>
        <city>Nan Chang</city>
        <state>Jiangxi</state>
        <zip>330006</zip>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>The Affiliated Hospital of Changchun University of Chinese Medicine</name>
      <address>
        <city>Chang Chun</city>
        <state>Jilin</state>
        <zip>130021</zip>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Shenyang He Eye Hospital</name>
      <address>
        <city>Shen Yang</city>
        <state>Liaoning</state>
        <zip>110141</zip>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Yantai Yuhuangding Hospital</name>
      <address>
        <city>Yan Tai</city>
        <state>Shandong</state>
        <zip>264000</zip>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Shanghai General Hospital</name>
      <address>
        <city>Shang Hai</city>
        <state>Shanghai</state>
        <zip>200080</zip>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Teaching Hospital of Chengdu University of TCM</name>
      <address>
        <city>Cheng Du</city>
        <state>Sichuan</state>
        <zip>610075</zip>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <verification_date>March 2017</verification_date>
  <study_first_submitted>March 2, 2015</study_first_submitted>
  <study_first_submitted_qc>March 9, 2015</study_first_submitted_qc>
  <study_first_posted type="Estimate">March 17, 2015</study_first_posted>
  <last_update_submitted>March 20, 2017</last_update_submitted>
  <last_update_submitted_qc>March 20, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">March 21, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Retinal Diseases</mesh_term>
    <mesh_term>Diabetic Retinopathy</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

